| Patient | Joe Frazier |
|---|---|
| Date of birth | 1944-01-12 |
| Identifiers | MRN HR-BX004-SYN-TD; SSN (made up) 000-04-5590 |
| Document date | 2008-04-13 |
| Author | Clarence Whitfield, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Eight-week review: blood pressure, lipids, kidney function, semaglutide and the endoscopy result. [S]
Mr. Frazier returns six weeks after the consultation. He took semaglutide 0.25 mg weekly for four weeks and has taken 0.5 mg for two weeks; he had mild nausea for two days after each step and none now, and no abdominal pain. His appetite is smaller and he has lost 1.8 kg. He takes amlodipine 5 mg; home readings average 136/84. He has had no alcohol. The upper endoscopy last week showed no varices. He attended the first diabetes class. His eye appointment is next month. [S]
| Element | Detail |
|---|---|
| Semaglutide | 0.25 mg for four weeks, 0.5 mg for two weeks; mild nausea after each step, now gone |
| Home blood pressure | Average 136/84 on amlodipine 5 mg |
| Endoscopy | No varices |
| Alcohol | None |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | Nausea after each dose step, now gone; no abdominal pain, vomiting or black stools |
| Cardiovascular | Negative | No ankle swelling or chest pain |
| Musculoskeletal | Negative | No muscle aches |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for years | One tablet twice daily with meals | Oral route | 2008-02-16 | active | S |
| Lisinopril 20 mg oral tablet, one tablet daily; taken for years | One tablet daily | Oral route | 2008-02-16 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2008-02-16 | active | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2008-03-02 to 2008-04-13 | completed | S |
| Amlodipine 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2008-04-13 | active | S |
| Semaglutide pen (0.25 mg or 0.5 mg per dose), 0.25 mg under the skin once weekly for four weeks, then 0.5 mg once weekly | 0.25 mg weekly for four weeks, then 0.5 mg weekly | Subcutaneous route | 2008-03-02 to 2008-05-18 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2008-04-13 | Body height | 182 | cm | S |
| 2008-04-13 | Body weight | 101.8 | kg | S |
| 2008-04-13 | Body mass index (BMI) [Ratio] | 30.7 | kg/m2 | S |
| 2008-04-13 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2008-04-13 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2008-04-13 | Heart rate | 72 | /min | S |
| 2008-04-13 | Respiratory rate | 16 | /min | S |
| 2008-04-13 | Body temperature | 36.7 | Cel | S |
| 2008-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2008-04-13 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2008-04-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.1 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2008-04-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2003)/1.73 sq M | 75 | mL/min/{1.73_m2} | 60 or higher without kidney damage markers is not CKD | Normal | S |
| 2008-04-13 | Cholesterol [Mass/volume] in Serum or Plasma | 148 | mg/dL | <=199 mg/dL | Normal | S |
| 2008-04-13 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 68 | mg/dL | Goal below 70 mg/dL with diabetes and other risk factors | Normal | S |
| 2008-04-13 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 40 | mg/dL | >=40 mg/dL | Normal | S |
| 2008-04-13 | Triglyceride [Mass/volume] in Serum or Plasma | 168 | mg/dL | <=149 mg/dL | High | S |
| 2008-04-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 44 | U/L | 10-40 U/L | High | S |
| 2008-04-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 40 | U/L | 7-55 U/L | Normal | S |
Vital signs recorded on 2008-04-13; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 134/82, pulse 72; weight 101.8 kg |
| Cardiovascular | No ankle edema |
| Abdomen | Soft and non-tender; no ascites |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes with hyperglycemia, about twelve years' duration, A1c 8.4% on metformin; synthetic modern episode linked to his publicly reported diabetes | active | confirmed | E11.65 | S — Synthetic modern diagnosis; diabetes was reported publicly during his life, but its duration and treatment here are synthetic. |
| Hypertension above goal on lisinopril (152/92 mmHg in the clinic); synthetic modern episode linked to his publicly reported high blood pressure | active | confirmed | I10 | S — Synthetic modern diagnosis; high blood pressure was reported publicly during his life. |
| Raised AST (48 U/L) with mildly low platelets (138) and a FIB-4 score of 3.43 at the yearly liver check, to be evaluated | resolved | confirmed | R74.01 | S — Synthetic presenting finding, superseded at the two-week visit by the elastography and ultrasound diagnosis. |
| Metabolic dysfunction-associated steatotic liver disease (MASLD): steatosis on elastography (controlled attenuation parameter 318 dB/m) and ultrasound, with diabetes, obesity, low HDL and high triglycerides, and little alcohol | active | confirmed | K76.0 | S — Synthetic modern diagnosis. Not part of the public record of his life; chosen to teach surveillance. |
| Compensated cirrhosis (compensated advanced chronic liver disease) from MASLD: liver stiffness 17.6 kPa, platelets 138, nodular liver surface and a spleen of 13.4 cm on ultrasound; no ascites, encephalopathy, bleeding or jaundice; Child-Pugh A | active | confirmed | K74.69 | S — Synthetic modern diagnosis. Not part of the public record of his life; the liver cancer diagnosed three years later in the true frame does not appear in the modern episode. |
| Hyperlipidemia: LDL 132 mg/dL, HDL 38 and triglycerides 210, not on a statin | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
| Obesity, class 1 (BMI 31.4) | active | confirmed | E66.811 | S — Synthetic finding; described without stigma. |
| Reduced vision in the left eye since a cataract found at 20 (counting fingers at 1 meter); right eye 20/30 | active | confirmed | H54.62 | S — Synthetic modern measurement anchored to the documented cataract in his left eye. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (clinic and home), weight and BMI | Every visit | Completed today | 134/82 in the clinic; home average 136/84; weight 101.8 kg |
| Laboratory | Potassium, creatinine and eGFR (CKD-EPI 2003) on lisinopril | Every 6 months on an ACE inhibitor, and after changes | Completed today | Potassium 4.7, creatinine 1.10 mg/dL, eGFR 75 |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin, then yearly | Completed today | Total 148, LDL 68, HDL 40, triglycerides 168 mg/dL |
| Laboratory | Liver tests with FIB-4 | With statin start and yearly | Completed today | AST 44, ALT 40 U/L |
| Laboratory | Hemoglobin A1c | Every 3 months until at goal or after a change in treatment, then every 6 months | Due | Due at three months, in five weeks |
| Medication safety | Semaglutide dose steps, nausea, abdominal pain, gallbladder and pancreatitis symptoms | At each dose step | Completed today | 0.5 mg weekly; transient nausea; no abdominal pain |
| Medication safety | Low blood sugar review and medicine tolerability | Every visit | Completed today | No low blood sugar |
| Referral | Variceal screening | Endoscopy when portal hypertension cannot be ruled out; repeat in 2 years if no varices and the liver injury continues | Completed today | Endoscopy last week: no varices; repeat in two years |
| Imaging | Liver ultrasound with AFP for hepatocellular carcinoma surveillance | Every 6 months in cirrhosis | Up to date | Baseline in March; next in September |
| Examination | Dilated eye examination | At the start of care, then every 1 to 2 years; promptly when A1c is falling quickly on a GLP-1 receptor agonist | Ordered | Eye clinic appointment next month |
| Self-management | Alcohol abstinence | Every visit | Completed today | No alcohol |
| Self-management | Diabetes self-management education | At the start of care and yearly | Completed today | First class attended |
| Self-management | Vaccines for diabetes and chronic liver disease | At diagnosis of chronic liver disease | Completed today | Hepatitis B dose 2 today; hepatitis A dose 2 in September |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2 [S]
Guideline basis: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023); Baveno VII - Renewing consensus in portal hypertension (2022); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026)
Follow-up: Three-month review in five weeks with the A1c and home readings. Eye clinic next month. Next scheduled visit 2008-05-18: three-month review: A1c, blood pressure, weight, semaglutide dose and the eye examination. [S]